The role of Cripto-1 in the tumorigenesis and progression of oral squamous cell carcinoma

Yoon, Hye‐Jung; Hong, Jisoo; Shin, Wui-Jung; Lee, Yoojin; Hong, Kyoung‐Ok; Lee, Jae‐Il; Hong, Sam-Pyo; Hong, Seong‐Doo

doi:10.1016/j.oraloncology.2011.07.019

Cited by 32 publications

(25 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Immunohistochemistry of the OSCC tumor tissue, in our study, reveals that 80% of the cases showed positivity for CR-1. This expression is more than that reported earlier for OSCC in literature [25]. However, we could not find significant correlation between tissue expression .…”

Section: Discussioncontrasting

confidence: 80%

See 1 more Smart Citation

Oncofetal Protein CR-1 in a new clinical role: a potential tumor marker for Oral Squamous Cell Carcinoma

Jain

Kumar

Thakur

et al. 2019

Preprint

View full text Add to dashboard Cite

PURPOSE: CR-1 (CR-1) is an oncofetal protein with its role as a key factor in early process of carcinoma has been evaluated in cases of various cancers. However, very few studies have reported its role in oral cancers, which is the sixth most common cancer around the world, particularly with high prevalence in developing countries. Oral squamous cell carcinoma (OSCC) is the most predominant (90%) of all the histological types of oral cancer. Late detection, associated with increased morbidity and mortality, is mainly attributed to non-availability of a suitable biomarker for the disease. In the present pilot study we have evaluated the role of soluble CR-1, in serum as a potential tumor marker for OSCC. METHODS: CR-1 was estimated using sandwich ELISA in serum samples of 50 biopsy proven OSCC patients (pre and post treatment) along with age and gender matched healthy controls. Immunohistochemistry was also done in corresponding tumor tissue sections to check the expression of CR-1. RESULTS: Pre-treatment CR-1 was found to be 2.25 fold higher in serum of OSCC patients as compared to control (p<0.0001***), which was reduced to 1.6 folds post treatment (p=0.0006***). CR-1 levels were comparatively higher in early stage of disease. Upon IHC 80% of the cases were found to be positive for CR-1. CONCLUSION: This study provides evidence that serum levels of CR-1 are elevated in patients of Oral Squamous Cell Carcinoma, which decrease post treatment. Also, the association of expression of protein with tumor progression predicts CR-1 as a molecule that can be further evaluated as a potential tumor maker in OSCC.

show abstract

Section: Discussioncontrasting

confidence: 80%

“…Yoon H.J. et al, in 2011, reported high expression of membrane bound CR-1 in tumor tissue of oral squamous cell carcinoma (OSCC) patients [25]. However, the study did not include the expression analysis of soluble form of CR-1.…”

Section: Introductionmentioning

confidence: 99%

Oncofetal Protein CR-1 in a new clinical role: a potential tumor marker for Oral Squamous Cell Carcinoma

Jain

Kumar

Thakur

et al. 2019

Preprint

View full text Add to dashboard Cite

show abstract

“…15 Others have reported the inhibition of cellular proliferation in HCT-8 human colon adenocarcinoma cells by alantolactone, which interrupts the Activin receptor type II A and Cripto-1 interaction. 16 Yoon et al 17 demonstrated Cripto-1-dependent increased proliferation of oral squamous carcinoma cells. Cripto-1 expressing cells have been identified in rapidly growing regions of the tumor, suggesting a possible link between GBM cell proliferation and Cripto-1 expression level.…”

mentioning

confidence: 99%

Investigating the role of CRIPTO‐1 (TDGF‐1) in glioblastoma multiforme U87 cell line

Alowaidi

Hashimi

Nguyen

et al. 2018

J of Cellular Biochemistry

View full text Add to dashboard Cite

Cripto‐1 has been implicated in a number of human cancers. Although there is high potential for a role of Cripto‐1 in glioblastoma multiforme (GBM) pathogenesis and progression, few studies have tried to define its role in GBM. These studies were limited in that Cripto‐1 expression was not studied in detail in relation to markers of cancer initiation and progression. Therefore, these correlative studies allowed limited interpretation of Criptos‐1's effect on the various aspects of GBM development using the U87 GBM cell line. In this study, we sought to delineate the role of Cripto‐1 in facilitating pathogenesis, stemness, proliferation, invasion, migration and angiogenesis in GBM. Our findings show that upon overexpressing Cripto‐1 in U87 GBM cells, the stemness markers Nanog, Oct4, Sox2, and CD44 increased expression. Similarly, an increase in Ki67 was observed demonstrating Cripto‐1's potential to induce cellular proliferation. Likewise, we report a novel finding that increased expression of the markers of migration and invasion, Vimentin and Twist, correlated with upregulation of Cripto‐1. Moreover, Cripto‐1 exposure led to VEGFR‐2 overexpression along with higher tube formation under conditions promoting endothelial growth. Taken together our results support a role for Cripto‐1 in the initiation, development, progression, and maintenance of GBM pathogenesis. The data presented here are also consistent with a role for Cripto‐1 in the re‐growth and invasive growth in GBM. This highlights its potential use as a predictive and diagnostic marker in GBM as well as a therapeutic target.

show abstract

“…Some candidates were then further evaluated in a protein folding comparison between the EGF domains, and the EGF domains from hCFC1 and mCripto-1 were significantly similar to hCripto-1. [40][41][42][43][44] In three of these five studies, the conclusions are significantly based on Ab19917 detection of cripto-1, all concluding cripto-1 expression as a functional marker of malignancy in different types of cancer. Considering this, at least cross-reactivity between the significant candidates should be tested.…”

Section: Discussionmentioning

confidence: 96%

“…Although without significant Z-score, the RMSD of the other EGF domains showed a value below the threshold of 2.5 Å, indicating a similar structure. 40,42,44 Most cripto-1 antibodies are polyclonal, elevating the risk of cross-reactivity. Cripto-1 and CFC1 proteins are both GPI-anchored and contain one EGF and one CFC domain, and have also been implicated in some of the same pathways with the same interaction partners, highlighting their similarity.…”

Section: Discussionmentioning

confidence: 99%

An evaluation of different Cripto‐1 antibodies and their variable results

Gudbergsson

Duroux

2019

J of Cellular Biochemistry

View full text Add to dashboard Cite

Cripto‐1 is a protein expressed during embryonal development and has been linked to several malignant processes in cancer. Since the discovery of cripto‐1 in the late 1980s, it has become a subject of biomarker investigation in several types of cancer which in many cases relies on immunolocalization of cripto‐1 using antibodies. Investigating cripto‐1 expression and localization in primary glioblastoma cells, we discovered nonspecific binding of cripto‐1 antibody to the extracellular matrix Geltrex. A panel of four cripto‐1 antibodies was investigated with respect to their binding to the Geltrex matrix and to the cripto‐1 positive control cells NTERA2. The cripto‐1 expression was varied for the different antibodies with respect to cellular localization and fixation methods. To further elaborate on these findings, we present a systematic review of cripto‐1 antibodies found in the literature and highlight some possible cross reactants with data on sequence alignments and structural comparison of EGF domains.

show abstract

The role of Cripto-1 in the tumorigenesis and progression of oral squamous cell carcinoma

Cited by 32 publications

References 28 publications

Oncofetal Protein CR-1 in a new clinical role: a potential tumor marker for Oral Squamous Cell Carcinoma

Oncofetal Protein CR-1 in a new clinical role: a potential tumor marker for Oral Squamous Cell Carcinoma

Investigating the role of CRIPTO‐1 (TDGF‐1) in glioblastoma multiforme U87 cell line

An evaluation of different Cripto‐1 antibodies and their variable results

Contact Info

Product

Resources

About